CITN and ION scientists are working on new ways to use the immune system’s innate disease-fighting abilities to help fight cancer. Different types of immunotherapies boost patients’ immune systems in different ways. These therapies may be used alone or together with similar therapies or with conventional cancer treatments.
In addition to nationwide trials coordinated by CITN and ION, Fred Hutch scientists conduct hundreds of clinical trials and volunteer studies.
Learn more about clinical trials and observational studies in this Fred Hutch Clinical Trials FAQ.
Bringing agents in development to patients who need them requires more than just committed researchers. CITN and ION partner with industry, government and biotech to access promising immunotherapy agents and design trials that can potentially lead to a regulatory approval pathway for the agent.
CITN and ION collaborate with biopharmaceutical partners to advance promising immunotherapy compounds to the clinic. We offer access to a proven clinical trials infrastructure that supports immunotherapy drug development from concept to market.
CITN and ION provide:
CITN and ION welcomes the opportunity to discuss strategic alliances and scientific advisory roles with the biopharmaceutical industry for compounds that have demonstrated cancer immune activity.
Foundations offer the opportunity to design and co-sponsor clinical trials. This accelerates effective immunotherapy development for a variety of cancers. CITN-ION has a strong track record of conducting robust and cost-effective trials with our centralized training, monitoring, and resource sharing.
Our nonprofit partners include: